Should Axsome’s New Solriamfetol Phase 3 and AXS-05 Priority Review Prompt Action From AXSM Investors?

Simply Wall St.03-10

Axsome Therapeutics recently dosed the first patient in its CLARITY Phase 3 trial of solriamfetol for major depressive disorder with excessive daytime sleepiness and has also been granted FDA Priority...

Source Link
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment